Arthasri Impex Private Limited
This company trades chemicals, bulk drugs, goods, and raw materials, and also manufactures and imports various products.
2011 | Hyderabad, Telangana (India) | Active
Arthasri Impex Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
- Paid Up Capital ₹ 7.51 M
- Company Age 14 Year, 16 Days
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -55.72%
- Profit Growth -265.76%
- Ebitda -222.51%
- Net Worth -11.64%
- Total Assets -20.21%
About Arthasri Impex
Arthasri Impex Private Limited (AIPL) is a Private Limited Indian Non-Government Company incorporated in India on 11 February 2011 and has a history of 14 years. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 7.51 M, as per Ministry of Corporate Affairs (MCA) records.
Chaitanya Madallapalli and Radhakrishna Jetty serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74900TG2011PTC072559
- Company No.
072559
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Feb 2011
- Date of AGM
21 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Pharma
Who are the key members and board of directors at Arthasri Impex?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chaitanya Madallapalli  | Director | 24-Feb-2023 | Current |
| Radhakrishna Jetty | Director | 06-Jan-2016 | Current |
Financial Performance of Arthasri Impex.
Arthasri Impex Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 55.72% decrease. The company also saw a substantial fall in profitability, with a 265.76% decrease in profit. The company's net worth observed a substantial decline by a decrease of 11.64%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Arthasri Impex?
In 2023, Arthasri Impex had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Srh Biopolymers Private Limited
Radhakrishna Jetty is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Arthasri Impex?
Unlock and access historical data on people associated with Arthasri Impex, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Arthasri Impex, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Arthasri Impex's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
